Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer

NCT01150513 is registered in ClinicalTrials.gov with Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT01150513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01150513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer
Lead sponsor
Chinese Academy of Medical Sciences
Phase
Phase 2/3
Overall status
Completed
Start date
June 30, 2009
Completion date
April 30, 2016
Enrollment
320 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer